Dr. Thomas Fellner is Head of Commercial Development for Cell Therapy at the Lonza Group, a Swiss company, headquartered in Basel, Switzerland. Since 1987, Lonza has been a leading custom manufacturer and developer, offering global services and products ranging from active pharmaceutical ingredients and stem-cell therapies to our clients globally.
In his current role, Dr. Fellner is responsible for the strategic development and planning, portfolio management, and business development for the cell therapy business. Previously, as Director of the Pluripotent Stem Cell Research team, Dr. Fellner was responsible for the development of new technologies, providing a comprehensive service offering to assist our clients, bridge the gap from research to cell therapy.
Before joining Lonza, Dr. Fellner was an integral part of the Human Embryonic Stem Cell Program at the University of California, San Diego (UCSD), USA. He gained his expertise in stem cell biology through appointments at Stanford University, USA and the University of California in Los Angeles (UCLA), USA. Dr. Fellner holds an MBA degree from the Rady School of Management at UCSD and a Ph.D. degree in Biochemistry from the University of Vienna, Austria.